Aprea Therapeutics Announces Presentation at the 35th

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
199
Aprea Therapeutics Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco

About Aprea Therapeutics AB

Aprea Therapeutics AB is a Boston, Massachusetts- and Stockholm, Sweden-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein, p53. The Company’s lead program, APR-246, a first-in-class small molecule drug candidate, is in Phase II clinical development in ovarian cancer patients, and additional clinical studies with APR-246 in other cancer indications are planned. In March 2016, Aprea completed a EUR 46 million Series B financing with an international syndicate co-led by Versant Ventures and 5AM Ventures, with additional participation by Sectoral Asset Management, HealthCap, acting as local lead investor, and existing investor, Karolinska Development. For more information, please visit www.apreatherapeutics.com.

 

About p53 and APR-246

The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors.  These mutations are often associated with resistance to anticancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer.

APR-246 has been shown to reactivate mutant p53 protein – by reconverting mutant p53 into wild-type p53 conformation and function – and thereby induce programmed cell death in human cancer cells.  APR- 246 has demonstrated compelling pre-clinical antitumor activity in a wide variety of solid and hematological (blood) tumors, including ovarian cancer, small cell lung cancer, esophageal cancer and AML (acute myeloid leukemia), among others.  Additionally, strong synergy has been seen with both traditional anticancer agents, such as chemotherapy, as well as newer mechanism-based anticancer drugs and immuno-oncology checkpoint inhibitors. In addition to pre-clinical testing, Phase I clinical studies with APR-246 have been completed, demonstrating a favorable safety profile and both biological and clinical responses in hematological malignancies and solid tumors with mutations in the p53 gene. The Company has commenced a Phase II study on ovarian cancer and is expecting to initiate additional clinical studies of APR-246 in other cancer indications.

 

Corporate Contacts:

Christian S. Schade

President and Chief Executive Officer

chris.schade@aprea.com

 

Gregory A. Korbel, Ph.D.

Vice President of Business Development

greg.korbel@aprea.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CSS Revamps Identity, Emphasizing Senior Living Tech

Updated Category News Views 5

CSS Takes a Bold Step with a Fresh Brand Identity Every now and then, you see a company shake off the old coat and put on a polished new one. That's what CSS is doing with its updated brand, staking its claim as a heavyweight tech player in the senior living sector. No small feat, given the challenges stacked against these aging communities—tasked with keeping...

Continue Reading
BMAP Expands: Bridging Borders in Legal Advocacy

Updated Category News Views 5

Breaking Down BMAP's Unique Approach Just when you thought you've seen it all, along comes LMU Loyola Law School swinging the doors wide open with their Binational Migrant Advocacy Project, or as we’re affectionately calling it, BMAP. It's a mouthful, sure, but ain't it something? This project isn't just another feather in academia's cap—it's a relentless counterpunch...

Continue Reading
Perk's U.S. Expansion: A Bold Move in Spend Control

Updated Category News Views 7

Perk Aims for U.S. Growth: Will It Pay Off? Amidst the cacophony of market chatter, Perk's announcement to bring its spend platform stateside is echoing louder than usual. This move is not just another step in its expansion but rather a leap considering the competition and market needs. In Europe, where they've already captured a chunk of the market with their Travel and...

Continue Reading
Lumicell Expands LumiSystem in Breast Cancer Surgery

Updated Category News Views 7

Innovation in Breast Cancer Surgery: A Real-World Game Changer? You’ve got your flashlight guiding a scared child through the dark, and in the healthcare world, Lumicell is promising to do just that for surgeons navigating the tricky maze of breast cancer surgery. Their LumiSystem is making waves in breast-conserving surgery—new kid on the block with a real chance at...

Continue Reading
NOAA Taps ICEYE US for Game-Changing SAR Satellite Data

Updated Category News Views 7

The Strategic Move to SAR Data Imagine this: You’re in the thick of a hurricane, where visibility goes out the window, and traditional satellite data chokes under the crushing weight of clouds and nightfall. That's the precise chaos ICEYE US is cutting through with its Synthetic Aperture Radar (SAR) technology. The latest scuttlebutt is that NOAA's getting cozy with...

Continue Reading
TWP & Commbi Unveil Exclusive Pony Clog Collaboration

Updated Category News Views 5

A Fusion of Fashion and Functionality Walk down the streets of New York or hustle your way through an airport without worrying about your footwear weighing you down. That's the promise coming from the fresh alliance between TWP and Commbi with their new Pony Clog Collaboration. A blend of high fashion and everyday utility, these clogs aren't just keeping up with the...

Continue Reading
Alcott HR's Sales Strategy Gets a Boost with New Hire

Updated Category News Views 9

Alcott HR Ramps Up Sales Firepower Now here's something fresh from the world of human resources outsourcing—Alcott HR has grabbed a new ace for their sales team. Eldin Radoncic is the name you'll want to remember, folks, because he's diving headfirst into the Director of Sales seat at this IRS Certified and ESAC Accredited player based out in good old Farmingdale, New...

Continue Reading
RxWellness Hits Inc. 5000—Four Straight Wins Impress

Updated Category News Views 6

RxWellness Spine & Health Continues to Impress Well, not many companies can boast about snagging a spot on the Inc. 5000 list four years in a row, but here we are with RxWellness Spine & Health doing just that. Sitting pretty at No. 1,230 nationally—and that's no small feat—these folks are making waves in the healthcare industry. Securing the No. 135 spot in...

Continue Reading
Robotics in Cleaning: 2026 Sees Double Adoption Rates

Updated Category News Views 4

Cleaning Industry Eyes Robotic Solutions Amid Labor Squeeze In a twist that's got industry veterans nodding knowingly, the cleaning industry is tipping towards automation. The recent 2026 Building Service Contractor Market Study reveals a massive leap: 32% of building service contractors (BSCs) plan to embrace robotic floor equipment in the coming year. That's a...

Continue Reading
Citrine Finalizes Sale of Illinois Senior Living Asset

Updated Category News Views 7

Citrine's Strategic Exit from River Glen Every now and then, you see a company pull off something that makes you nod and say, "That was smart." Citrine Investment Group's sale of River Glen of St. Charles fits that bill. For those keeping tabs, this wasn't some quick flip—Citrine worked on the rock for a good while before cashing in. They secured River Glen back in...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Overview: Notable Stocks Dip Ahead of Trading

Updated Category News Views 95

Market Trends Impacting Major Stocks This morning, the U.S. stock futures displayed mixed signals, with the Dow futures taking a step back, dropping around 50 points. Baidu's Market Performance Baidu, Inc. (NASDAQ: BIDU) experienced a significant decline during the pre-market hours, with shares falling by 2.6% to $101.08. This downturn follows disappointing response to...

Continue Reading
XPLR Infrastructure Investors: Important Class Action Update

Updated Category News Views 122

Class Action Lawsuit for XPLR Infrastructure Investors Attention to all investors who purchased units of XPLR Infrastructure, LP, formerly known as NextEra Energy Partners, LP (NYSE: XIFR). Recently, a significant class action lawsuit has been initiated by Wolf Haldenstein Adler Freeman & Herz LLP. This legal action concerns individuals and entities who have experienced...

Continue Reading
Atos Partners with Invictus Games for a Transformative Experience

Updated Category News Views 258

Atos Partners with Invictus Games for a Transformative Experience Atos, recognized as a leader in digital transformation, has been appointed as the Official Technology Partner for the Invictus Games Vancouver Whistler 2025. This exciting partnership signifies a commitment to providing advanced Timing, Results, and Scoring Solutions to enhance the games slated for...

Continue Reading
California Water Service Group Addresses Rate Increase Proposal

Updated Category News Views 169

Significant Water Rate Adjustment Initiative by California Water Service In a recent step to enhance the quality of water service, California Water Service Group's subsidiary Washington Water Service has approached the Washington Utilities and Transportation Commission to request an increase in water rates. This decision comes in light of the company’s investment of...

Continue Reading
Provident Industrial Completes Sale of Key Logistics Facility

Updated Category News Views 105

Provident Industrial Sells Building III at Gateway Logistics Park Provident Industrial, a division of Dallas-based Provident, has finalized the sale of Building III at Gateway Logistics Park. The buyer is EQT Exeter, a global real estate firm with a wide-ranging portfolio that spans logistics, industrial, and residential assets across multiple continents. The transaction...

Continue Reading